Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry

Journal of Proteome Research

Volumn 7, Issue 8, 2008, Pages 3146-3158

  Garbis, Spiros D ^a   Tyritzis, Stavros I ^b   Roumeliotis, Theodoros ^a   Zerefos, Panagiotis ^a   Giannopoulou, Eugenia G ^c   Vlahou, Antonia ^a   Kossida, Sophia ^a   Diaz, Jose ^d   Vourekas, Stavros ^b   Tamvakopoulos, Constantin ^a   Pavlakis, Kitty ^b   Sanoudou, Despina ^a   Constantinides, Constantinos A ^b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF PELOPONNESE   (Greece)

^d CTRC Institute for Drug Development   (United States)

Author keywords

Biomarkers; iTRAQ; LC MS; Prostate cancer; Proteomics

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; AGED; AMINO ACID SEQUENCE; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REPRODUCIBILITY;

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEOME; TUMOR MARKER;

AGED; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOME; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 53049090352     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800060r     Document Type: Article

References (64)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C; Thun, M. J. Cancer statistics 2006. CA Cancer J. Clin. 2006, 429 (56), 106- 130.
2. Balk, S. P.; Ko, Y.; Bubley, G. J. Biology of Prostate-Specific Antigen. J. Clin. Oncol. 2003, 21, 383-391.
3. Thompson, I. M.; Ankerst, D. P.; Chi, C; Lucia, M. S.; Goodman, P. J.; Crowley, J. J.; Parnes, H. L.; Coltman, C. A. Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. JAMA. 2005, 294, 66-70.
4. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents. Mol. Cell. Proteomics. 2004, 3, 1154-1169.
5. Mueller, M. M.; Fusenig, N. E. Friends of Foes-bipolar Effects of the Tumour Stroma in Cancer. Nat. Rev. Cancer 2004, 4, 839-849.
6. Joyce, J. A. Theraupeutic Targeting of the Tumour Microenviron-ment. Cancer Cell 2005, 7, 513-520.
7. Applied Biosystems iTRAQ Reagents Amine-Modifying Labeling Reagents for Multiplexed Relative and Absolute Protein Quantitation: Applied Biosystems, Protocol. Copyright 2004.
8. Shilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The Paragon Algorithm: A Next Generation Search Engine that Uses Sequence Temperature Values and Feature Probabilities to Identify Peptides from Tandem Mass Spectra. Mol. Cell. Proteomics 2007, 6, 1638-1655.
9. Camon, E.; Barrell, D.; Lee, V.; Dimmer, E.; Apweiler, R. The Gene Ontology Annotation (GOA) Database - An Integrated Resource of GO Annotations to the UniProt Knowledgebase. In Silico Biol. 2004, 4, 5-6.
10. DeSouza, L.; Diehl, G.; Rodrigues, M. J.; Guo, J.; Romaschin, A. D.; Colgan, T. J.; Siu, M. K. W. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and 1CAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2005, 4, 377-386.
11. DeSouza, L.; Grigull, J.; Ghanny, S.; Dubé, V.; Romaschin, A. D.; Colgan, T. J.; Siu, M. K. W. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics 2007, 6, 2648-2655.
12. Hammarsten, J.; Högstedt, B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand. J. Urol. Nephrol. 2002, 36, 330-338.
13. Diamandis, E. P. Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool. Mol. Cell. Proteomics 2004, 3, 367-378.
14. Everley, P. A.; Krijgsveld, J.; Zetter, B. R.; Gygi, S. P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol. Cell. Proteomics 2004, 3, 729-735.
15. Wright, M.; Han, D.; Aebersold, R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol. Cell. Proteomics 2005, 4, 545-554.
16. Hood, B. L.; Darfler, M. M.; Guiel, T. G.; Furusato, B.; Lucas, D. A.; Ringeisen, B. R.; Sesterhenn, I. A.; Conrads, T. P.; Veenstra, T. D.; Krizman, D. B. Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue. Mol. Cell. Proteomics 2005, 4, 1741-1753.
17. Comuzzi, B.; Sadar, M. D. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cell Sci. 2006, 3, 61-81.
18. Martin, D. B.; Gifford, D. R.; Wright, M. E.; Keller, A.; Goodlett, D. R.; Aebersold, R.; Nelson, P. S. Quantitavive proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res. 2004, 64, 347-355.
19. Wright, M. E.; Eng, J.; Sherman, J.; Hockenbery, D. M.; Nelson, P. S.; Galitski, T.; Aebersold, R. Identification of androgen-coregultated protein networks from the microsomes of human prostate cancer cells. Genome Biol. 2003, 5, R4.
20. Meehan, K. L.; Sadar, M. D. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 2004, 4, 1116-1134.
21. Glen, A.; Gan, C. S.; Hamdy, F. C.; Eaton, C. L.; Cross, S. S.; Catto, J. W. F.; Wright, P. C; Rehman, I. iTRAQ-Facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res. 2008, 7, 897-907.
22. Everlay, P. A.; Krijgsveld, J.; Zetter, B. R.; Gygi, S. P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol. Cell. Proteomics 2004, 3, 729-735.
23. Hood, B. L.; Darfler, M. M.; Guiel, T. G.; Furusato, B.; Lucas, D. A.; Ringeisen, B. R.; Sesterhenn, I. A.; Conrads, T. P.; Veenstra, T. D.; Krizman, D. B. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol. Cell. Proteomics 2005, 4, 1741-1753.
24. Wu, W. W.; Wang, G.; Baek, S. J.; Shen, R-F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D Gel- or LC-MALDI TOF/TOF. J. Proteome Res. 2006, 5, 651-658.
25. Rowland, J. G.; Robson, J. L.; Simon, W. J.; Leung, H. Y.; Slabas, A. R. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 2007, 7, 47-63.
26. DeMarzo, A. M.; Nelson, W. G.; Isaacs, W. B.; Epstein, J. I. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361 (9361), 955-964.
27. Nelson, W. G.; De Marzo, A. M.; DeWeese, T. L.; Isaacs, W. B. The role of inflammation in the pathogenesis of prostate cancer. J. Urol. 2004, 172 (5), S6-S12.
28. Albini, A.; Tosetti, F.; Benelli, R.; Noonan, D. M. Tumour inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005, 65, 10637-10641.
29. Mcllwain, C. C; Townsend, D. M. Tew KD: Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006, 25, 1639-1648.
30. Yan, X.-D.; Pan, L.-Y.; Yuan, Y.; Lang, J. H.; Mao, N. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 2007, 6, 772-780.
31. Murakami, M.; Kudo, I. Prostaglandin E synthase: A novel drug target for inflammation and cancer. Curr. Pharm. Des. 2006, 12 (8), 943-954.
32. Kuvibidila, S.; Rayford, W. Correlation between serum prostate- specific antigen and alpha-l-antitrypsin in men without and with prostate cancer. J. Lab. Clin. Med. 2006, 147, 174-181.
33. Lattouf, J.-B.; Srinivasan, R.; Pinto, P. A.; Linehan, W. M.; Neckers, L. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat. Clin. Pract. Urol. 2006, 3, 590-601.
34. Milad, M.; Sullivan, W.; Diehl, E.; Altmann, M.; Nordeen, S.; Edwards, D. P.; Toft, D. O. Interaction of the progesterone receptor with binding proteins for FK506 and cyclosporin A. Mol. Endocrinol. 1995, 9 (7), 838-847.
35. Miyoshi, Y.; Ishiguro, H.; Uemura, H.; Fujinami, K.; Miyamoto, H.; Miyoshi, Y.; Kitamura, H.; Kubota, Y. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003, 56 (4), 280-286.
36. Cheung-Flynn, J.; Prapapanich, V.; Cox, M. B.; Riggs, D. L.; Suarez- Quian, C; Smith, D. F. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 2005, 19 (6), 1654-1666.
37. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
38. Yong, W.; Yang, Z.; Periyasamy, S.; Chen, H.; Yusel, S.; Li, W.; Lin, L. Y.; Wolf, I. M.; Cohn, M. J.; Baskin, L. S.; Sanchez, E. R.; Shou, W. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 2007, 282 (7), 5026-5036.
39. Menendez, A. J.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer. 2007, 7 (10), 763-777.
40. McCarty, M. F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. Int. Cancer Th. 2004, 3 (4), 349-380.
41. Carnell, A. J.; Hale, I.; Denis, S.; Wanders, R. J. A.; Isaacs, W. B.; Wilson, B. A.; Ferdinandusse, S. Design, synthesis, and in vitro testing of r-methylacyl-CoA racemase inhibitors. J. Med. Chem. 2007, 50, 2700-2707.
42. Browne, T.; Hirsch, M.; Brodsky, G.; Welch, W.; Loda, M.; Rubin, M. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum. Pathol. 2004, 35 (12), 1462-1468.
43. Vanguri, V. K.; Woda, B. A.; Jiang, Z. Sensitivity of P504S/alpha- methyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies. Appl. Immunohistochem. Mol. Morphol. 2006, 14 (3), 365-368.
44. Okuda, M.; Horn, H.; Tarapore, P.; Tokuyama, Y.; Smulian, A.; Chan, P.; Knudsen, E.; Hofmann, I.; Snyder, J.; Bove, K. Nuleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000, 103 (1), 127-140.
45. Grisendi, S.; Mecucci, C; Falini, B.; Pandolfi, P. P. Nucleophosmin and cancer. Nat. Rev. Cancer. 2006, 6, 493-505.
46. Shao, R.; Bao, S.; Bai, X.; Blanchette, C; Anderson, R. M.; Dang, T.; Gishizky, M. L.; Marks, J. R.; Wang, X.-F. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 2004, 24 (9), 3992-4003.
47. Bao, S.; Ouyang, G.; Bai, X.; Huang, Z.; Ma, C; Liu, M.; Shao, R.; Anderson, R. M.; Rich, J. N.; Wang, X.-F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5 (4), 329- 339.
48. Wang, W.; Eddy, R.; Condeelis, J. The cofilin pathway in breast cancer invasion and metastasis. Nat. Rev. Cancer 2007, 7, 429-440.
49. Hale, L. P.; Price, D. T.; Sanchez, L. M.; Demark-Wahnefried, W.; Madden, J. F. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin. Cancer Res. 2001, 7 (4), 846-853.
50. Yu, Y. P.; Luo, J. H. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res. 2006, 166 (15), 7414-7419.
51. Davies, G.; Ablin, R. J.; Mason, M. D.; Jiang, W. G. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J. Exp. Ther. Oncol. 2007, 6 (3), 257-264.
52. Lescuyer, P.; Hochstrasser, D.; Rabilloud, T. How shall we use the proteomics toolbox for biomarker discovery. J. Prof. Res. 2007, 6, 3371-3376.
53. Tamvakopoulos, C. Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom. Rev. 2007, 26 (3), 389-402.
54. Yang, M.; Sytkowski, A. J. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998, 15, 58 (14), 3150-3153.
55. Jerónimo, C; Henrique, R.; Oliveira, J.; Lobo, F.; Pais, I.; Teixeira, M. R.; Lopes, C. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J. Clin. Pathol. 2004, 57 (8), 872-876.
56. Cleaver, J. E.; Thompson, L. H.; Richardson, A. S.; States, J. C. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Hum. Mutat. 1999, 14 (1), 9-22.
57. Deep, G.; Agarwal, R. Chemopreventive efficacy of siiymarin in skin and prostate cancer. Integr. Cancer Ther. 2007, 6 (2), 130-145.
58. Shih, I-M. The role of CD 146 (Mel-CAM) in biology and pathology. J. Pathol. 1999, 189, 4-11.
59. Albini, A.; Sporn, M. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 2007, 7, 139-147.
60. Shimura, S.; Yang, G.; Ebara, S.; Wheeler, M. T.; Frolov, A.; Thompson, T. C. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000, 60, 5857-5861.
61. Aboulaich, N.; Ortegren, U.; Vener, A. V.; Strålfors, P. Association and insulin regulated translocation of hormone-sensitive lipase with PTRF. Biochem. Biophys. Res. Commun. 2006, 350 (3), 657- 661.
62. Khanna, C; Wan, X.; Bose, S.; Cassaday, R.; Olomu, O.; Mendoza, A.; Yeung, C; Gorlick, R.; Hewitt, S. M.; Helman, L. J. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 2004, 10, 182-186.
63. Weng, W.-H.; Åhlen, ].; Åstrom, K.; Lui, W.-Cv, Larsson, C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin. Cancer Res. 2005, 11, 6198-6204.
64. Scorilas, A.; Gregorakis, A. K. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biol. Chem. 2006, 387 (6), 789-793.